The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical approvals , /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel (NurOwn®). The Company will share the data with an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers dedicated to ALS research at The 3rd Annual ALS Drug Development Summit, to take place in Stacy Lindborg PhD will deliver a presentation on new biomarker data from the NurOwn Expanded Access Program (EAP) along with data from the Phase 3 trial.
"We are very pleased to share these important outcome data from the NurOwn EAP with the ALS community," said Dr. , Member of BrainStorm's Board of Directors. "The data demonstrate a consistent reduction of neurofilament light (NfL) from baseline among participants who were randomized to receive NurOwn in the Phase 3 study.
This reduction in NfL observed during the randomized Phase 3 trial, as well as in the subsequent EAP periods, indicate that patients treated with NurOwn during the Phase 3 study see benefits from the extended treatment. Furthermore, participants initially .
